259 related articles for article (PubMed ID: 26961176)
21. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
Pintus G; Tadolini B; Posadino AM; Sanna B; Debidda M; Bennardini F; Sava G; Ventura C
Eur J Biochem; 2002 Dec; 269(23):5861-70. PubMed ID: 12444974
[TBL] [Abstract][Full Text] [Related]
23. Suppression of anoikis in human intestinal epithelial cells: differentiation state-selective roles of α2β1, α3β1, α5β1, and α6β4 integrins.
Beauséjour M; Thibodeau S; Demers MJ; Bouchard V; Gauthier R; Beaulieu JF; Vachon PH
BMC Cell Biol; 2013 Dec; 14():53. PubMed ID: 24289209
[TBL] [Abstract][Full Text] [Related]
24. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
25. Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line.
Nakahara S; Miyoshi E; Noda K; Ihara S; Gu J; Honke K; Inohara H; Kubo T; Taniguchi N
Mol Cancer Ther; 2003 Nov; 2(11):1207-14. PubMed ID: 14617794
[TBL] [Abstract][Full Text] [Related]
26. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
27. N-acetylglucosaminyltransferase V negatively regulates integrin α5β1-mediated monocyte adhesion and transmigration through vascular endothelium.
Yang HM; Yu C; Yang Z
Int J Oncol; 2012 Aug; 41(2):589-98. PubMed ID: 22614033
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
Tan C; Hu S; Liu J; Ji L
Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
[TBL] [Abstract][Full Text] [Related]
29. Ruthenium complexes can target determinants of tumour malignancy.
Bergamo A; Sava G
Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
[TBL] [Abstract][Full Text] [Related]
30. Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Bult A; Beijnen JH
J Pharm Biomed Anal; 2002 Nov; 30(4):1287-96. PubMed ID: 12408919
[TBL] [Abstract][Full Text] [Related]
31. The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.
Vadori M; Florio C; Groppo B; Cocchietto M; Pacor S; Zorzet S; Candussio L; Sava G
J Biol Inorg Chem; 2015 Jul; 20(5):831-40. PubMed ID: 25982099
[TBL] [Abstract][Full Text] [Related]
32. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G
Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599
[TBL] [Abstract][Full Text] [Related]
33. Role of α5β1 and αvβ3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions.
Stachurska A; Elbanowski J; Kowalczyńska HM
Cell Biol Int; 2012 Oct; 36(10):883-92. PubMed ID: 22686483
[TBL] [Abstract][Full Text] [Related]
34. Regulation of ionizing radiation-induced adhesion of breast cancer cells to fibronectin by alpha5beta1 integrin.
Lee SH; Cheng H; Yuan Y; Wu S
Radiat Res; 2014 Jun; 181(6):650-8. PubMed ID: 24785587
[TBL] [Abstract][Full Text] [Related]
35. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
36. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
39. The integrin alpha5beta1 regulates alphavbeta3-mediated extracellular signal-regulated kinase activation.
Ly DP; Corbett SA
J Surg Res; 2005 Feb; 123(2):200-5. PubMed ID: 15680379
[TBL] [Abstract][Full Text] [Related]
40. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
